Daniel is a Managing Director of Broadview Ventures, a mission-driven early-stage investor focused on improving human health in the areas of cardiovascular disease and stroke, where he leads the MedTech practice and oversees Broadview investment operations and organizational development.Prior to Broadview, he held a variety of operational, corporate venture, and business development roles at Proteon Therapeutics, Abbott Vascular, and Guidant. Daniel currently holds board positions at Alleviant, XII Medical, Cardiosense, CroíValve, Nyra Medical and CorFlow, and previously held board positions at Nido Surgical (acquired) and Puzzle Medical, and as a member of Guidant Compass at CardioMEMS (acquired) and Neovasc (acquired). Daniel holds a BA from the University of Pennsylvania and an MBA from the Tuck School of Business at Dartmouth.